top of page
Search

Aegis Capital Corp. acted as Sole Bookrunner on a $10.0 Million Underwritten Public Offering for Sunshine Biopharma, Inc.

New York, New York / GLOBE NEWSWIRE/ February 15, 2024 / Aegis Capital Corp. acted as Sole Bookrunner on a $10.0 Million Underwritten Public Offering for Sunshine Biopharma, Inc. (NASDAQ: SBFM).


About Sunshine Biopharma, Inc.


Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements.


For more information, please visit: https://sunshinebiopharma.com




About Aegis Capital Corporation 


Aegis Capital Corporation ("Aegis") has been in the wealth management and investment banking business since 1984. Aegis is dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis also provides research, sales and trading services to institutional and retail investors. Aegis offers its investment representatives a conflict free service platform and is able to provide a full-range of products and services including investment banking, wealth management, insurance, retirement planning, structured products, private equity, alternatives, equity research, fixed income and special purpose vehicles.


For more information about this offering or Investment Banking Services please email Banking@aegiscap.com or call (212) 813-1010.






       www.aegiscapcorp.com


Brokerage and investment advisory services are offered through Aegis Capital Corporation, a member of FINRA and SIPC.  Investment and insurance products offered are not insured by the FDIC or any other federal government agency, are not deposits or other obligations of, or guaranteed by, a bank or any bank affiliate, and are subject to investment risks, including possible loss of the principal amount invested.


194 views0 comments

Comments


bottom of page